GlassScriptPhysician profile
Peter Robert Coelho
NPI 1285740480
$6,923.24
in general payments reported to CMS, 2019-2025
26 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,575 · 2020: $249 · 2021: $490 · 2022: $2,895 · 2023: $267 · 2024: $131 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,689.35 | 2021-2025 | Vraylar |
| Terumo Medical Corporation | $2,100.00 | 2019 | |
| Glaxosmithkline, LLC. | $627.33 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $253.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $210.36 | 2019-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $195.08 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $181.81 | 2019-2021 | |
| Coala Life INC | $133.76 | 2021-2023 | Coala Heart Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $119.93 | 2022-2024 | |
| Amgen INC. | $48.07 | 2019-2023 | Repatha, Otezla |
| Avanir Pharmaceuticals, INC. | $41.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.38 | 2019-2022 | |
| Exact Sciences Corporation | $34.68 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $32.28 | 2023 | |
| Lilly USA, LLC | $28.87 | 2022-2023 | Jardiance, Emgality |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.26 | 2019-2022 | |
| Optinose US, INC. | $24.00 | 2019 | |
| Eisai INC. | $21.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.74 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.66 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $16.32 | 2025 | Dupixent |
| Verity Pharmaceuticals INC. | $14.68 | 2025 | Tlando |
| Depuy Synthes Sales INC. | $13.92 | 2025 | Monovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $13.84 | 2023 | Glassia |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Merck Sharp & Dohme LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Coelho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.